Dr. John studies the malaria parasite, Plasmodium falciparum, to understand its basic molecular and cellular biology and functions of its specific metabolic pathways — what the parasite needs to make and why it needs to make it — to identify new antimalarial drug targets and develop new diagnostics.
Dr. Rivella is an expert in the pathophysiology of erythroid and iron disorders and in the generation of lentiviral vectors for the cure of hemoglobinopathies. He also investigates additional disorders such as anemia of inflammation and hemochromatosis.
Dr. Jacobs’s current research focuses on several areas, including the biochemical, microbiological, and genetic cause of scarring or stenosis of the laryngotracheal airway, and the development of tissue-engineered cartilage and other novel biomaterials for laryngotracheal reconstruction. Dr. Jacobs is also investigating the mitigation of button battery injuries in infants and children
Dr. Gottardi leads the Bioengineering and Biomaterials (Bio2) lab, collaborating on clinical and research efforts to offer engineering solutions for pediatric health, primarily treatments for airway disorders. Dr. Gottardi researches mechanisms of laryngotracheal pathologies, applies tissue engineering to improve pediatric conditions, develops new devices, and formulates controlled drug delivery systems to treat and improve patients’ lives.
The founder and director of CHOP's Center for Fetal Diagnosis and Treatment, Dr. Adzick is an innovator in the field of fetal medicine, pursuing groundbreaking prenatal treatment for debilitating birth defects. He led the NIH-funded "Management of Myelomeningocele Study" (MOMS) at CHOP, a breakthrough research program that showed fetal surgery for spina bifida results in significantly improved outcomes.
Dr. Gmuca seeks to enhance the care of children with chronic musculoskeletal pain. Her current research addresses amplified musculoskeletal pain syndrome, which is a major public health issue because of its high prevalence, related socioeconomic burden, and associated risk of opioid exposure. Dr. Gmuca’s work aims to identify innovative strategies to improve long-term treatment outcomes for this patient population.
Dr. Tong investigates cytokine receptor signaling in normal and neoplastic hematopoietic development. She uses integrated approaches encompassing biochemistry, molecular biology, mouse models, and primary human samples to understand signaling events emanating from cytokine receptors that regulate the development of hematopoietic stem/progenitor cells.